Biosyn corp news

Twenty-seven and counting – biosyn’s global expansion strategy

Twenty-seven and counting – biosyn’s global expansion strategy

Developing pharmaceutical-grade trace elements for marketing is a long-term venture: It can take up to decades to go from the trial laboratory to applications in humans. Then comes the total procedure time companies need to invest in applying for and being granted marketing authorization. Now multiply that figure by 27. That would come close to equaling the effort biosyn Arzneimittel GmbH invested in obtaining licenses to sell its products around the globe.

Read more...

A pioneer of IMMUCOTHEL has passed

A pioneer of IMMUCOTHEL has passed

The urologist Karl-Friedrich Klippel was intensely focused on bladder cancer. He has now died at the age of 76. biosyn Arzneimittel GmbH will always hold his name in honorable remembrance. At our biotechnology corporation, the former president of the German non-profit Society of Biological Cancer Defense (Gesellschaft für Biologische Krebsabwehr e.V.) was a major force driving the development of and providing scientific support for IMMUCOTHEL, our drug for the management of superficial carcinoma of the urinary bladder, also referred to as non-muscle-invasive bladder cancer (NMIBC).

Read more...

After celebrating the 20th anniversary of World Cancer Day biosyn reinforces its commitment to cancer research and awareness

After celebrating the 20th anniversary of World Cancer Day biosyn reinforces its commitment to cancer research and awareness

The theme of World Cancer Day is “I am and I will” to let individuals and companies show how they are committed to act in preventing cancer. In 2020, biosyn joined the organizers in the initiative led by the Union for International Cancer Control (UICC) in speaking out and standing up for a cancer-free world and shared its own stories like those by its production manager Dr. Büchler and its favorite sea snail.

Read more...

A tale of two subunits: KLH 1 and KLH 2 in Immucothel

A tale of two subunits: KLH 1 and KLH 2 in Immucothel

Themes of earthly duality have been inspirations throughout history, for example, compelling Charles Dickens to write about two contrasting cities, Goethe’s character Faust to lament the two competing souls in his breast and Shakespeare’s Hamlet to confront the choice between life and death. The exploration of dichotomies by novelists and poets has produced great works of literature and expanded our insights into the human situation. The same holds true for researchers and science.

Read more...

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

The memory loss disorder eponymously called Alzheimer's burdens around 44 million people worldwide, according to the statistics reported by “Alzheimer’s News Today”. The prevalence of this neurodegenerative disease is as pathologically progressive as is its clinical course. Absent any cure or any way to stop or slow progression, the only options are symptomatic treatments and coping strategies for patients and their loved ones. Therefore, many committed researchers have long set their sights on developing a vaccine to ward off the disease’s neurodegenerative mental decline.

Read more...

biosyn’s CEO explains how the company’s keyhole limpet hemocyanin helps fight recurrences in superficial bladder cancer

Megathura crenulata

In the early 1990s, the team of researchers around Dr. Thomas Stiefel, CEO of the pharmaceutical company biosyn, discovered that a unique sea creature living in the cold waters off Southern California’s Pacific coastline can provide a substance for use in cancer therapy. Keyhole limpet hemocyanin (KLH), an immunostimulating glycoprotein, is obtained by a non-lethal method from the hemolymph of the keyhole limpet (Megathura crenulata).

Read more...

biosyn scientist and KLH researcher Dr. Kay Büchler shares his story for World Cancer Day 2020

The theme of World Cancer Day 2020 is "I am and I will" to let individuals tell about how they are committed to act in preventing cancer. One of biosyn’s own has shared his story: "My name is Dr. Kay Büchler. I am 42 years old and work as a production manager in drug research and development. After my doctoral studies in biology, I wanted to work on research into something that is not just theory, but can be applied clinically and is effective. Something that makes an impact in real life and is ultimately used on real patients. I looked to data for my answer and chose a biotech company in the pharmaceutical industry that uses very large protein molecules from a natural living source to help treat cancer. Bladder cancer. The molecules that we extract non-lethally from the Californian Keyhole Limpet are purified to an active ingredient and instilled into the urinary bladder. Because they are so big and different from naturally occurring human proteins, they stop recurrence by stimulating the immune system to fight any tumor cells trying to grow back. This therapy lowers the growth rate and acts with few side effects."

Read more...

biosyn’s Keyhole Limpet shares its story

My name is Megathura crenulata and I live in the cold coastal waters of Southern California’s and Baja Mexico’s Pacific rim. I am a marine mollusk that gives of itself to beat cancer. Every now and then, divers swim by my habitat to collect me and my comrades for our work in the fight against cancer. They gently take us to the biosyn labs where we are kept in cooled metal basins. As a gastropod, what flows through my veins is not mammalian blood, but hemolymph. The scientists in the lab extract this from my single foot to make immunocyanin, a powerful vaccine instilled in the bladder for cancer recurrence.

Read more...

Mechanism for stimulating anti-tumor immune responses: How Keyhole Limpet Hemocyanin (KLH) antibodies detect and destroy bladder cancer cells

Numerous oligosaccharides are attached to the surface of the KLH molecule and account for about 4% of its molecular mass. With their intricate topology, these oligosaccharides contribute to KLH’s strong immunogenicity. Although not completely elucidated, different mechanisms of action are at play: non-specific stimulation of the immune system, stimulation of cytotoxic T cells and induction of anti-tumoral antibodies. KLH antibodies can bind to the Thomsen-Friedenreich antigens associated with cancer progression and metastasis on bladder carcinoma cells. The reaction of KLH antibody with Thomsen-Friedenreich antigen leads to phagocytosis and dissolution of the tumor cell. Immunocyanin, the main ingredient in IMMUCOTHEL® for the recurrence prevention of superficial urinary bladder carcinoma, is derived from KLH.

Read more...

German know-how. American ingenuity. Good Manufacturing Practice for global hemocyanin products thrives in California.

Since its founding in Carlsbad, California in 1995, biosyn Corporation has driven the development, manufacturing and marketing of hemocyanin and immunocyanin products forward. With German know-how, American ingenuity and the help of a California resident, the first hemocyanin product was approved in 1997. Ever since, biosyn has been the leading manufacturer of high-quality, clinical-, GMP- and research-grade hemocyanin products extracted from the Giant Keyhole Limpet. The anticancer drugs, immunotherapeutics and carrier-proteins for vaccines evolved from this combination benefit patients around the globe.

To learn more about Good Manufacturing Practice (GMP) at biosyncorp, visit biosyncorp.com/about-us/

Hope is the color blue. The unique IMMUCOTHEL® from the keyhole limpet indicated for the prevention of superficial bladder cancer recurrence.

What to do when the standard fails? Wasn't it enough that the patient suffered from superficial bladder cancer and now a post-TUR recurrence? After standard therapies were contraindicated, have been exhausted or were not tolerated in the first place, second-line treatment with IMMUCOTHEL® is indicated to prevent recurrences in superficial bladder cancer. This immunotherapeutic from biosyn is a safe, efficacious and well-established alternative to BCG. Thanks to its high tolerability and low rate of side effects, patients experience much less distress with IMMUCOTHEL®.

Read more...